HelyerL.K., BrienC.O, CoburnN.G.: Improving the quality of surgery for gastric cancer: are surgeons aware of the relevant quality indicators?Proc ASCO2006, abstract 4048.
2.
YchouM., PignonJ.P., LasserP.: Phase III preliminary results of preoperative 5FU and cisplatin versus surgery alone in adenocarcinoma of the stomach and lower esophagus.Proc ASCO2006, abstract 4026.
3.
CunninghamD.: Perioperative chemotherapy in operable gastric and lower esophageal cancer: final results of a randomised, controlled trial (the MAGIC trial).Proc ASCO2005, abstract 4001.
4.
SakamotoJ., TsuburayaA., MoritaS.: Adjuvant chemotherapy with UFT for gastric cancer: a meta-analysis of centrally randomized clinical trials.Proc ASCO2006, abstract 4033.
5.
Di FabioF., PintoC., FantiS.: 18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction adenocarcinoma: first results of the italian FOLCETUX study.Proc ASCO2006, abstract 4061.
6.
CunninghamD., RaoS., StarlingN.: Randomised multicentre phase III comparing capecitabine with 5FU and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: the REAL-2 trial.Proc ASCO2006, LBA 4017.
7.
Al-BatranS., HartmannJ., ProbstS.: A randomised phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with FLO vs FLP.Proc ASCO2006, LBA 4016.
8.
KangY., KangW.K., ShinD.B.: Randomised phase III trial of XP vs FP as first-line therapy in patients with advanced gastric cancer: efficacy, and safety results.Proc ASCO2006, LBA 4018.
9.
TebbuttN., GebskiV., StricklandA.: Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophagogastric cancer.Proc ASCO2006, abstract 4067.
10.
RanaV., KrishnanS., AbbruzzeseJ.L.: Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer.Proc ASCO2006, abstract 4036.
11.
ChauffertB., MornexF., BonnetainF.: Phase III trial comparing initial CT/RT followed by GEM vs GEM alone in patients with locally advanced non metastatic pancreatic cancer.Proc ASCO2006, abstract 4008.
12.
NeoptolemosJ.P., StockenD.D., FriessH.: A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.N Engl J Med 2004;350: 1200–1210.
13.
KhoranaA.A., FrancisC.W., RyanK.C.: Tissue factor, angiogenesis and thrombosis in pancreatic cancer.Proc ASCO2006, abstract 4001.
14.
BriaE., CarliniP., GelibterA.: Current status of targeted agents in advanced pancreatic cancer: a pooled analysis of 2361 pts enrolled in six phase III trials.Proc ASCO2006, abstract 4126.
15.
LouvetC., HinckeA., LabiancaR., HeinemannV.: Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer: pooled analysis of two randomised trials: the GERCOR/GISCAD Intergroup Study and a German Multicenter Study.Proc ASCO2006, abstract 4003.
16.
PoplinE., LevyD.E., BerlinJ.: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion) versus GEMOX in patients with advanced pancreatic cancer (E6201).Proc ASCO2006, LBA 4004.
17.
RegineW.F., WinterK.W., AbramsR.: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation 5FU vs gemcitabine for resected pancreatic adenocarcinoma.Proc ASCO2006, abstract 4007.
18.
NeuhausP., HoettleH., PostS.: A randomised prospective multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (CONKO 001).Proc ASCO2005, LBA 4013.
19.
DeschC.E.: Post-treatment surveillance for colorectal cancer.ASCO Educational Book, 175–178, 2006.
20.
ColucciG., GiulianiF., MattioliR.: FOLFOX4 + cetuximab in untreated patients with advanced CRC: a phase II study of the GOIM (protocol GOIM 2402).Proc ASCO2006, abstract 3559.
21.
DakhilS., CosgriffT., HeadleyD.: Cetuximab + FOLFOX 6 as first-line therapy for metastatic CRC: an International Oncology Network Study I-03-002.Proc ASCO2006, abstract 3557.
22.
BornerM., MingroneW., KoeberleD.: The impact of cetuximab on XELOX combination in first-line treatment of metastatic CRC: a randomised phase II trial of the SAKK.Proc ASCO2006, abstract 3551.
23.
HeinemannV., FischerL., MoosmannN.: Cetuximab + XELIRI vs cetuximab + XELOX as first-line therapy for patients with metastatic CRC: preliminary results of a randomised phase II trial of the AIO CRC study group.Proc ASCO2006, abstract 3550.
24.
PessinoA., ArtaleS., GuglielmiA.: First-line single agent cetuximab in patients with advanced colorectal cancer.Proc ASCO2006, abstract 3553.
25.
KozloffM., HainsworthJ., BadarinathS.: Efficacy of bevacizumab plus CT as first-line treatment of patients with metastatic CRC: updated results from a large observational registry in the US (BRiTE).Proc ASCO2006, abstract 3537.
26.
HurwitzH., FehrehnbacherL., NovotnyW.: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med 2004;350: 2335–2342.
27.
HedrickE., KozloffM., HainsworthJ.: Safety of bevacizumab plus CT as first-line treatment of patients with metastatic CRC: updated results from a large observational registry in the US (BRiTE).Proc ASCO2006, abstract 3536.
28.
BerryS.R., CunninghamD., MichaelM.: Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC – First BEA Trial.Proc ASCO2006, abstract 3534.
29.
CannistraS.A., MatulonisU., PensonR.: Bevacizumab in patients with advanced platinum-resistant ovarian cancer.Proc ASCO2006, abstract 5006.
30.
KabbinavarF.F., HambletonJ., MassR.D.: Combined analysis of efficacy: the addition of bevacizumab to 5FU/LV improves survival for patients with metastatic CRC.J Clin Oncol 2005;23: 3706–3712.
31.
Maindrault-GoebelF., LledoG., ChibaudelB.: OPTIMOX 2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic CRC: a GERCOR study.Proc ASCO2006, abstract 3504.
32.
LabiancaR., FlorianiI., CortesiE.: Alternating versus continuous FOLFIRI in advanced CRC: a randomized GISCAD trial.Proc ASCO2006, abstract 3505.
33.
CarrateA., KohneC., BedenneL.: Folinic acid modulated bolus 5FU or infusional 5FU for adjuvant treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC 2 study.Proc ASCO2006, abstract 3563.
34.
FalconeA., MasiG., BrunettiI.: The triplet combination of irinotecan, oxaliplatin and 5FU/LV vs the doublet of irinotecan and 5FU/LV as first-line treatment of metastatic colorectal cancer: results of a randomised phase III trial by the GONO.Proc ASCO2006, abstract 3513.
35.
SouglakosJ., AndroulakisN., SyrigosK.: FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicenter randomised phase III trial from the Hellenic Oncology Research Group (HORG).Br J Cancer 2006;94: 798–805.
36.
HallerD.G., CassidyJ., ClarkeS.: Tolerability of fluoropyrimidines appears to differ by region.Proc ASCO2006, abstract 3514.
37.
GruenbergerT., SorbyeH., DeboisM.: Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983.Proc ASCO2006, abstract 3500.
38.
EllisJ.M., CurleyS.A., GrotheyA.: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.J Clin Oncol 2005;23: 4853–4855.
39.
MitryE., FieldsA., BleibergH.: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a meta-analysis of two randomised trials.Proc ASCO2006, abstract 3524.
40.
AjaniA.J., WinterK.A., GundersonL.L.: Intergroup RTOG 9811: a phase III randomised study of 5FU, mytomicin and radiotherapy versus 5FU, cisplatin and RT in carcinoma of the anal canal.Proc ASCO2006, abstract 4009.
41.
AlexopoulosC.G., KotsoriA.A.: Continuous vs intermittent chemotherapy in metastatic CRC.Proc ASCO2006, abstract 3582.
42.
PlantadeA., AlchainP., TournigandC.: Chemotherapy-free intervals in patients with metastatic CRC.Proc ASCO2006, abstract 3581.
